L-type calcium channel trafficking and modulation in heart

心脏中 L 型钙通道的运输和调节

基本信息

  • 批准号:
    9054912
  • 负责人:
  • 金额:
    $ 57.6万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-08-01 至 2018-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The cardiac L-type Ca2+ channel plays a key role in cardiac excitation-contraction coupling, action potential duration, and gene expression. Abnormalities in CaV1.2 function, including increased long-opening-mode gating and blunted adrenergic responsiveness, are associated with heart failure and hypertrophy. The increased activation of CaV1.2, in turn, triggers Ca2+-responsive signaling pathways, which contribute to the pathogenesis of heart failure and hypertrophy. Proper targeting of CaV1.2 to distinct surface sites, and hormonal regulation of their activity, is vital for normal cardiac physiology. Cav1.2 in heart is associated with large supramolecular complexes that impact on channel trafficking, localization, turnover, and function. Much of the prevailing dogma relating to mechanisms underlying CaV1.2 trafficking and modulation is derived from studies using recombinant channels reconstituted in heterologous expression systems. However, recent results using knock-in mice indicate that several long-standing "facts" about CaV1.2 regulation derived from heterologous expression studies are not replicated in native heart, emphasizing the critical need for mechanistic studies in the context of actual cardiomyocytes. For instance, a 96% reduction of CaVβ2 protein expression in adult murine cardiomyocytes caused only a ~29% reduction in CaV1.2 currents, challenging conventional wisdom, based on heterologous expression studies, that binding to β is absolutely required for α1C trafficking to the cell surface. We have developed two complementary novel tools to express informative α1C mutants within the context of cardiomyocytes: (a) Intein-mediated protein ligation enables robust reconstitution of dihydropyridine (DHP)-resistant α1C subunits in ventricular myocytes using two adenoviruses containing N- and C-terminal halves of α1C. This strategy circumvents the need to generate viruses encoding the entire α1C, which is technically challenging due to the large insert size. (b Transgenic mice conditionally expressing doxycycline-inducible, cardiac-specific DHP-resistant α1C harboring mutations and truncations of putative regulatory sites in adult cardiomyocytes and at all stages of development. We propose to determine in cardiomyocytes: (1) the role of β subunit binding to α1C for CaV1.2 trafficking, function and adrenergicmodulation in cardiomyocytes; (2) the role and mechanisms by which α1C C-terminus regulates CaV1.2 trafficking and functional modulation in heart; (3) elucidate determinants underlying CaV1.2 functional targeting to dyads in cardiomyocytes by replacing the intracellular domains of the T-type Ca2+ channel (α1G), which is excluded from t-tubules, with the corresponding intracellular segments of the L-type Ca2+ channel (α1C). The three Aims, which should provide key new understandings concerning the regulation of Ca2+ influx in cardiomyocytes, are highly relevant towards understanding cardiac pathologies and the molecular mechanisms responsible for cardiac excitation-contraction coupling and adrenergic modulation of the cardiac Ca2+ channel.
描述(由申请人提供):心脏L型Ca 2+通道在心脏兴奋-收缩偶联、动作电位持续时间和基因表达中起关键作用。CaV1.2功能异常,包括长开放模式门控增加和肾上腺素能反应性减弱,与心力衰竭和心肌肥厚相关。CaV1.2的激活增加,反过来,触发Ca 2+响应信号通路,这有助于心力衰竭和肥大的发病机制。将CaV1.2正确靶向不同的表面位点,以及激素对其活性的调节,对于正常的心脏生理学至关重要。Cav1.2 in 心脏与影响通道运输、定位、周转和功能的大的超分子复合物相关。大多数与CaV1.2运输和调节机制相关的流行教条来自使用在异源表达系统中重建的重组通道的研究。然而,最近使用敲入小鼠的结果表明,几个长期存在的“事实”CaV1.2的调节来自异源表达的研究是不复制在天然心脏,强调迫切需要在实际的心肌细胞的背景下的机制研究。例如,成年鼠心肌细胞中CaVβ2蛋白表达降低96%仅导致CaV 1.2电流降低约29%,这挑战了基于异源表达研究的传统观点,即α1C运输至细胞表面绝对需要与β结合。我们已经开发 两种互补的新工具来表达心肌细胞内的信息α1C突变体:(a)内含肽介导的蛋白连接能够使用两种含有α1C的N-和C-末端一半的腺病毒在心室肌细胞中稳健地重建二氢吡啶(DHP)抗性α1C亚基。这种策略避免了产生编码整个α1C的病毒的需要,由于插入片段大小较大,这在技术上具有挑战性。(B)在成年心肌细胞和发育的所有阶段条件性表达强力霉素诱导的、心脏特异性DHP抗性α 1 C的转基因小鼠,该α 1 C携带推定调节位点的突变和截短。我们拟在心肌细胞中研究:(1)β亚基与α1C结合在心肌细胞CaV 1.2运输、功能和肾上腺素能调节中的作用;(2)α1C C末端在心脏CaV 1.2运输和功能调节中的作用和机制;(3)阐明CaV1.2通过替换T型Ca 2+通道的胞内结构域而靶向心肌细胞中二联体的功能决定因素(α1G),其被排除在t-小管之外,与L-型Ca 2+通道(α1C)的相应细胞内片段。这三个目标,这应该提供关键的新的理解有关的Ca 2+流入心肌细胞的调节,是高度相关的了解心脏病理和心脏兴奋收缩耦合和肾上腺素能调节心脏Ca 2+通道的分子机制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Henry M. Colecraft其他文献

Decoding polyubiquitin regulation of KV7. 1 (KCNQ1) surface expression with engineered linkage-selective deubiquitinases
利用工程化的连接选择性去泛素化酶解码 KV7.1(KCNQ1)表面表达的多聚泛素调节
  • DOI:
    10.1038/s41467-025-60893-0
  • 发表时间:
    2025-07-01
  • 期刊:
  • 影响因子:
    15.700
  • 作者:
    Sri Karthika Shanmugam;Scott A. Kanner;Xinle Zou;Enoch Amarh;Papiya Choudhury;Rajesh Soni;Robert S. Kass;Henry M. Colecraft
  • 通讯作者:
    Henry M. Colecraft
Multiple Mechanisms and Determinants Underlie Rem Inhibition of Voltage-dependent Calcium (Ca<sub>V</sub>) Channels
  • DOI:
    10.1016/j.bpj.2008.12.878
  • 发表时间:
    2009-02-01
  • 期刊:
  • 影响因子:
  • 作者:
    Tingting Yang;Henry M. Colecraft
  • 通讯作者:
    Henry M. Colecraft
Rem Selectively Abolishes β1-adrenergic Regulation Of Ca<sub>V</sub>1.2 Channels In Heart
  • DOI:
    10.1016/j.bpj.2008.12.1926
  • 发表时间:
    2009-02-01
  • 期刊:
  • 影响因子:
  • 作者:
    Xianghua Xu;Henry M. Colecraft
  • 通讯作者:
    Henry M. Colecraft
Beta-Adrenergic Stimulation of CAV1.2 Channels is Transduced via the IS6-Aid Linker
  • DOI:
    10.1016/j.bpj.2019.11.238
  • 发表时间:
    2020-02-07
  • 期刊:
  • 影响因子:
  • 作者:
    Arianne Papa;Jared Kushner;Jessica Hennessey;Alexander N. Katchman;Sergey I. Zakharov;Bi-xing Chen;Lin Yang;Ree Lu;Stephen Leong;Johanna Diaz;Henry M. Colecraft;Geoffrey S. Pitt;Manu Ben-Johny;Steven O. Marx
  • 通讯作者:
    Steven O. Marx
Bidirectional modulation of ion channels with divalent nanobodies
  • DOI:
    10.1016/j.bpj.2021.11.819
  • 发表时间:
    2022-02-11
  • 期刊:
  • 影响因子:
  • 作者:
    Travis J. Morgenstern;Arden Darko-Boateng;Papiya Choudhury;Sri Karthika Shanmugam;Xinle Zou;Henry M. Colecraft
  • 通讯作者:
    Henry M. Colecraft

Henry M. Colecraft的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Henry M. Colecraft', 18)}}的其他基金

Novel Tools to Probe Trafficking and Function of Calcium Channel Signaling Complexes in Heart
探测心脏钙通道信号复合物的运输和功能的新工具
  • 批准号:
    10628914
  • 财政年份:
    2023
  • 资助金额:
    $ 57.6万
  • 项目类别:
Structure-Function of Calcium Channel Complexes in Cardiac Physiology and Disease
钙通道复合物在心脏生理和疾病中的结构-功能
  • 批准号:
    10628911
  • 财政年份:
    2023
  • 资助金额:
    $ 57.6万
  • 项目类别:
Novel genetically-encoded inhibitors to probe functional logic of Cav-beta molecular diversity
新型基因编码抑制剂探索 Cav-beta 分子多样性的功能逻辑
  • 批准号:
    10581282
  • 财政年份:
    2022
  • 资助金额:
    $ 57.6万
  • 项目类别:
Towards Novel Therapies for CACNA1A Neurological Disorders
寻找 CACNA1A 神经系统疾病的新疗法
  • 批准号:
    10589799
  • 财政年份:
    2022
  • 资助金额:
    $ 57.6万
  • 项目类别:
Nanobodies for Probing CACNA2D2 and CACNA2D3 Function, Expression, and Therapeutics
用于探测 CACNA2D2 和 CACNA2D3 功能、表达和治疗的纳米抗体
  • 批准号:
    10217683
  • 财政年份:
    2021
  • 资助金额:
    $ 57.6万
  • 项目类别:
FASEB SRC on Ion Channel Regulation
FASEB SRC 关于离子通道调节
  • 批准号:
    9756745
  • 财政年份:
    2019
  • 资助金额:
    $ 57.6万
  • 项目类别:
Ubiquitin Regulation of K Channels in Health and Disease
K 通道在健康和疾病中的泛素调节
  • 批准号:
    10470075
  • 财政年份:
    2018
  • 资助金额:
    $ 57.6万
  • 项目类别:
Mechanisms of Long QT Syndrome 1 in Heart
心脏长 QT 综合征 1 的机制
  • 批准号:
    9038483
  • 财政年份:
    2016
  • 资助金额:
    $ 57.6万
  • 项目类别:
L-type calcium channel trafficking and modulation in heart
心脏中 L 型钙通道的运输和调节
  • 批准号:
    9266817
  • 财政年份:
    2014
  • 资助金额:
    $ 57.6万
  • 项目类别:
Small G-protein Regulation of Calcium Channels
小 G 蛋白对钙通道的调节
  • 批准号:
    8695923
  • 财政年份:
    2014
  • 资助金额:
    $ 57.6万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 57.6万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 57.6万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 57.6万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 57.6万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 57.6万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 57.6万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 57.6万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 57.6万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 57.6万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 57.6万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了